▼ -17.03% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Dechra Pharmaceuticals in the last 3 months. The average price target is GBX 3,438.33, with a high forecast of GBX 3,600 and a low forecast of GBX 3,200. The average price target represents a -17.03% upside from the last price of GBX 4,144.
The current consensus among 3 investment analysts is to buy stock in Dechra Pharmaceuticals. This rating has held steady since August 2019, when it changed from a Hold consensus rating.
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.